Establishment Labs (NASDAQ:ESTA) Lowered to "Sell" Rating by Wall Street Zen

Establishment Labs (NASDAQ:ESTA - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Thursday.

Other analysts have also issued reports about the stock. BTIG Research initiated coverage on shares of Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective for the company. Stephens reaffirmed an "overweight" rating and issued a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Finally, Needham & Company LLC raised shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 price target for the company in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $55.33.

Establishment Labs Trading Up 1.3%

Shares of NASDAQ:ESTA traded up $0.46 during trading on Thursday, reaching $37.08. 125,454 shares of the company traded hands, compared to its average volume of 472,063. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $58.00. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -14.37 and a beta of 0.73. The business's fifty day moving average is $34.26 and its 200-day moving average is $37.74.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $41.38 million for the quarter, compared to analyst estimates of $41.15 million. During the same quarter last year, the firm earned ($0.58) EPS. The company's revenue was up 11.3% on a year-over-year basis. As a group, analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Establishment Labs in the 4th quarter worth approximately $5,494,000. KLP Kapitalforvaltning AS bought a new position in Establishment Labs in the fourth quarter worth approximately $161,000. Swiss National Bank increased its stake in shares of Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares in the last quarter. Sei Investments Co. increased its holdings in Establishment Labs by 22.3% in the 4th quarter. Sei Investments Co. now owns 42,471 shares of the company's stock worth $1,957,000 after acquiring an additional 7,731 shares in the last quarter. Finally, Royce & Associates LP purchased a new position in Establishment Labs during the fourth quarter valued at approximately $4,862,000. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.